Loading...
Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)
n/a
n/a
stuart_roberts's Fair Value
n/a
1Y
-12.8%7D
0%1Y
-12.8%7D
0%You can edit this narrative until Dec 13 3:55 AM. Then, changes will post as Updates.